Periodic reminder that OpenAI got its big break when nvidia gave it free hardware to develop on that wasn’t widely available to rest of market at time
![In April 2016, OpenAl released a public beta of "OpenAl Gym", its platform for reinforcement learning research. 30. Nvidia gifted its first DGX-1 supercomputer to OpenAl in August 2016 to help it train larger and more complex Al models with the capability of reducing processing time from six days to two hours. 31[32 In December 2016, OpenAl released "Universe",
software platform for measuring and training an Al's general intelligence across the world's supply of games, websites, and other apicatons. 3[34[35][36]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:qju5a3556voxaxqs2jg4ekit/bafkreicdqqqhfdtctt65zob6d6tn5ikfovmhah3efgtihwvo55zr2pnopu)
October 8, 2025 at 10:12 AM
Periodic reminder that OpenAI got its big break when nvidia gave it free hardware to develop on that wasn’t widely available to rest of market at time
🧬 Un estudio internacional liderado por la UCAM demuestra que una dosis reducida de apixabán es eficaz y más segura en pacientes con cáncer tras 6 meses de tratamiento. Publicado en The New England Journal of Medicine.
www.laopiniondemurcia.es/comunidad/20...
www.laopiniondemurcia.es/comunidad/20...
Una investigación abre nuevas vías para el cuidado de pacientes con cáncer
El estudio, denominado Apicat para el ‘cuidado prolongado’ ha sido publicado en la prestigiosa revista científica 'The New England Journal of Medicine'
www.laopiniondemurcia.es
August 17, 2025 at 7:11 AM
🧬 Un estudio internacional liderado por la UCAM demuestra que una dosis reducida de apixabán es eficaz y más segura en pacientes con cáncer tras 6 meses de tratamiento. Publicado en The New England Journal of Medicine.
www.laopiniondemurcia.es/comunidad/20...
www.laopiniondemurcia.es/comunidad/20...
Extended reduced-dose DOAC: APICAT / RENOVE - Prof. Isabelle Mahé / Prof. Francis Couturaud
youtu.be/RXttWKQ-sM4?...
Prof Mahé and Prof. Couturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
youtu.be/RXttWKQ-sM4?...
Prof Mahé and Prof. Couturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
Extended reduced-dose DOAC: APICAT / RENOVE - Prof. Isabelle Mahé / Prof. Francis Couturaud
YouTube video by MARKUS at HOMe
youtu.be
August 15, 2025 at 4:50 PM
Extended reduced-dose DOAC: APICAT / RENOVE - Prof. Isabelle Mahé / Prof. Francis Couturaud
youtu.be/RXttWKQ-sM4?...
Prof Mahé and Prof. Couturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
youtu.be/RXttWKQ-sM4?...
Prof Mahé and Prof. Couturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
The apicat trial did study apixaban dose reduction VS full dose. That study makes me very comfortable using apixaban in this setting
June 24, 2025 at 12:20 PM
The apicat trial did study apixaban dose reduction VS full dose. That study makes me very comfortable using apixaban in this setting
#APICAT trial at #ACC25 #LBCT #cardioonc
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
March 29, 2025 at 3:34 PM
#APICAT trial at #ACC25 #LBCT #cardioonc
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE
#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
March 29, 2025 at 3:29 PM
Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE
#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky